Studies Document Improved Skin Appearance, Decreased Fine Lines
BOTHELL, Wash.--(Business Wire)--
Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today
announced the completion of a series of three clinical studies investigating the
safety and efficacy of a serum, eye cream and moisturizer, each containing the
Company`s SmartPeptides technology, including the newly developed
Heptapeptide-7. These studies demonstrate improvement in skin texture and
appearance as well as the decrease in fine lines and wrinkles with Striking Skin
Care formulations.
"Our SmartPeptides technology found in Striking Skin Care products performed
well in clinical evaluation with high consumer appeal," said Dr. Tim Falla,
Chief Scientific Officer at Helix BioMedix. "We are delighted with the results
of these third-party studies documenting the benefits of SmartPeptides
technology for people seeking improved skin texture and hydration. We plan to
present the studies at upcoming dermatology conferences, while we wait for
publication of the complete study."
The Company is in the process of submitting study synopsis articles for
publication in leading peer reviewed journals.
All three studies were conducted by Essex Testing Clinic, Inc (Verona, NJ) over
an eight week period with evaluations at baseline, eight hours and at two, four
and eight weeks. Evaluations consisted of physician and patient assessments as
well as measurements of skin hydration, topography and texture using
Corneometer, Visia CR and ImagePro instrumentation.
Summary findings of the studies are as follows:
SERUM: In a 32 person study (average age 54) the Striking Skin Care serum
produced a statistical improvement in vertical forehead lines with 74% of
subjects showing improvement. A statistical improvement was also seen in skin
texture with 87% of subjects showing improvement. Reductions in forehead
wrinkles could be seen as early as two weeks in certain individuals.
EYE: A 30 person study (average age 52) documented a statistical reduction in
the appearance of crow`s feet was seen with 97% of subjects showing improvement.
From the earliest time point of 8 hours, subjects exhibited a statistical
improvement in skin texture and moisturization with 100% and 83% showing
improvement respectively.
MOISTURIZER: In a 30 person study (average age 51) the Striking Skin Care
moisturizer produced a statistical improvement in skin hydration at all time
points from 8 hours through 8 weeks with 87% of participants showing
improvement. Statistical improvement in skin texture was also seen with 87% of
people showing an improvement; in certain individuals this was apparent after
only two weeks.
No irritation or adverse effects were reported throughout these third party
studies or in repeat patch test insult studies run in parallel. In all studies
statistical significance was taken as p ≤ 0.005.
About Heptapetide-7
Heptapeptide-7 is the latest advance in peptide technology from Helix BioMedix.
This bioactive peptide has been shown in vitro to promote keratinocyte
proliferation and migration, to support skin renewal, and to stimulate the
production of collagen strengthening skin structure. A SmartPeptides technology,
Heptapeptide-7 helps restore tone and firmness of perimenopausal and menopausal
hormonally challenged skin while decreasing the appearance of fine lines and
wrinkles.
About Helix BioMedix, Inc.
Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of
diverse bioactive peptides and patents covering six distinct classes and
hundreds of thousands of peptide sequences. Core competencies include peptide
design, synthesis and characterization together with assay development,
screening, tissue culture and microbiology, leveraged through relationships with
contract research organizations and peptide manufacturers. The company takes
product development programs from theoretical concept to a validated and
qualified skin care active ingredient fully validated as to efficacy and safety.
Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin
care and acne treatment as well as other topical anti-infective pharmaceuticals
and wound healing applications. Striking, SmartPeptides and HB-Aminobright are
trademarks of Helix BioMedix, Inc. More information about the company and its
proprietary peptides may be found on the company`s website at
www.helixbiomedix.com.
Forward Looking Statements
This press release contains forward-looking statements (statements which are not
historical facts) within the meaning of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements include statements regarding
activities, events or developments that the company expects, believes or
anticipates may occur in the future, including statements related to its
potential growth, product development and commercialization and revenue. A
number of factors could cause actual results to differ from those indicated in
the forward-looking statements, including the company's ability to successfully
raise additional capital, enter into revenue generating license agreements,
continue its research and development efforts, including pre-clinical and
clinical studies,and continue developing marketable peptide-based products, and
general economic conditions. Additional assumptions, risks and uncertainties are
described in detail in the company`s reports and other filings with the
Securities and Exchange Commission. Such filings are available on the company`s
website or at www.sec.gov. Readers are cautioned that such forward-looking
statements are not guarantees of future performance and that actual results or
developments may differ materially from those set forth in the forward-looking
statements. The company undertakes no obligation to publicly update or revise
forward-looking statements to reflect subsequent events or circumstances.
Investor Contact:
Shelton Group Investor Relations
Matt Kreps, 972-239-5119 X 125
mkreps@sheltongroup.com
or
Company Contact:
Helix BioMedix, Inc.
R. Stephen Beatty, 425-402-8400
President and CEO
sbeatty@helixbiomedix.com
Copyright Business Wire 2009
